Corvus Pharmaceuticals CRVS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's cash & equivalents?
- Corvus Pharmaceuticals (CRVS) reported cash & equivalents of $40.1M in Q1 2026.
- How has Corvus Pharmaceuticals's cash & equivalents changed year-over-year?
- Corvus Pharmaceuticals's cash & equivalents increased by 702.2% year-over-year, from $5M to $40.1M.
- What is the long-term trend for Corvus Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's cash & equivalents has grown at a -22.6% compound annual growth rate (CAGR), from $16.46M to $4.58M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.